Compare Vale SA (VALE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vale SA vs State Street SPDR S&P Biotech ETF — how do they compare? Vale SA trades at $15.44 (market cap $65.56B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Vale SA pays a 7.65% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vale SA nearer its low. Which is the better fit depends on your goals.
| VALE | XBI | |
|---|---|---|
Market Cap | $65.56B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $17.82 | $169.55 |
52-Week Low | $10.50 | $93.43 |
Enterprise Value | $81.80B | — |
Dividend Yield | 7.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VALE trades at $15.56, up 1.9% today, with a bullish technical signal and mixed fundamentals. Recent earnings missed estimates, but cash flow improved to $2.42B in 2025. The company maintains a stable dividend and sees iron ore demand as resilient, per CFO comments on September 9, 2026.
Outlook is cautious due to declining profit margins and rising debt, but analyst consensus suggests modest upside to a $16.25 price target. Risks include commodity price volatility and operational costs, while institutional interest remains steady.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
